文献速递肝病

脂肪性肝病的长期临床结局及肝脏相关事件、心血管事件和全因死亡率的发生率

Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
PubMed 文献 · Aliment Pharmacol Ther · 2024-04-25

这项全国性人群研究纳入761,400例MASLD、MetALD或ALD患者,评估肝脏相关事件、主要不良心血管事件(MACE)和死亡风险。肝脏相关事件和死亡累积发生率以ALD最高、MetALD次之、MASLD最低(均p < 0.001),MACE发生率以MASLD最高(p < 0.001)。以MASLD为参照调整混杂后,MetALD的肝脏相关事件aHR为1.42(1.1-1.8),ALD为3.42(2.6-4.6)。

要点

  • 肝脏相关事件和死亡累积发生率:ALD最高,MetALD次之,MASLD最低(均p < 0.001)。
  • MACE发生率:MASLD最高,MetALD次之,ALD最低(p < 0.001)。
  • 以MASLD为参照,ALD肝脏相关事件aHR 3.42(2.6-4.6),MetALD aHR 1.42(1.1-1.8)。

核心结论

  • 新共识命名可用于分层并发症风险和预后,有助于风险分层和识别疾病特异性治疗机制。

研究设计与样本

  • 全国性、基于人群的研究,纳入761,400例诊断为MASLD、MetALD或ALD的患者。

主要发现

  • 肝脏相关事件和死亡累积发生率以ALD最高、MetALD次之、MASLD最低(均p < 0.001),MACE发生率以MASLD最高、MetALD次之、ALD最低(p < 0.001)。
  • 以MASLD为参照并调整年龄、性别、吸烟、糖尿病、血脂异常和高血压后,MetALD的肝脏相关事件、MACE和死亡aHR分别为1.42(1.1-1.8)、0.68(0.63-0.73)和1.13(0.98-1.3)。
  • ALD的肝脏相关事件、MACE和死亡aHR分别为3.42(2.6-4.6)、0.58(0.49-0.67)和1.60(1.3-2.0)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A multi-society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic-dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol-associated liver disease (ALD). However, the risk of liver-related events, major adverse cardiovascular events (MACE) and all-cause mortality among various sub-groups is unknown. AIMS: To evaluate the risk of liver-related events, MACE and death among patients with SLD. METHODS: We conducted a nationwide, population-based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver-related events, MACE and death in patients with MASLD, MetALD and ALD. RESULTS: The cumulative incidence of liver-related events and death were highest in ALD, followed by MetALD and MASLD (p < 0.001 for both liver-related events and death), while the incidence of MACE was highest in MASLD, followed by MetALD and ALD (p < 0.001). Using MASLD as the reference and adjusting for age, sex, smoking, diabetes mellitus, dyslipidaemia and hypertension, the adjusted hazard ratios (95% confidence intervals) for liver-related events, MACE and death in MetALD were 1.42 (1.1-1.8), 0.68 (0.63-0.73) and 1.13 (0.98-1.3), respectively. In ALD, they were 3.42 (2.6-4.6), 0.58 (0.49-0.67) and 1.60 (1.3-2.0), respectively, for liver-related events, MACE and death. CONCLUSIONS: The new consensus nomenclature can be used to stratify the risk of complications and prognosis. The nomenclature is beneficial for risk stratification and identifying new mechanisms for disease-specific therapeutic implications.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tamaki N, Kimura T, Wakabayashi SI, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther. 2024. PMID: 38664876. doi:10.1111/apt.18015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。